Abstract
Pro-inflammatory cytokine over-expression may be implicated to the pathogenesis of anemia in chronic heart failure (CHF) through the suppression of bone marrow erythropoiesis. Erythropoietin administration has anti-inflammatory and anti-apoptotic properties in experimental CHF models and improves exercise capacity in anemic CHF patients. The present study investigates the effects of recombinant human erythropoietin analogue darbepoetin-α on circulating pro-inflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with CHF and anemia. Forty-one CHF patients (NYHA class: II–III; left ventricular (LV) ejection fraction (EF) <40%; hemoglobin <12.5 g/dl; serum creatinine <2.5 mg/dl) were randomized to receive either 3-month darbepoietin-α at 1.5 μg/kg every 20 days plus iron orally ( n = 21) or placebo plus iron orally ( n = 20). LV systolic function, plasma B-type natriuretic peptide (BNP), inflammatory markers (TNF-α, IL-6, CRP), anti-inflammatory cytokine IL-10, endothelial adhesion molecules (soluble ICAM-1 and VCAM-1) and soluble apoptosis mediators (soluble Fas, soluble Fas ligand), and 6-min walking distance were assessed at baseline and 3 months post-treatment. In darbepoetin-α treated patients, plasma BNP (451 (62-2770) from 802 (476-4440) pg/ml, p = 0.002), IL-6 (6.5 ± 4.7 from 10.5 ± 7.8 pg/ml, p = 0.013) and soluble Fas ligand (53.2 ± 16.6 from 59.2 ± 17.9 pg/ml, p = 0.023) decreased significantly, while LVEF (32 ± 6 from 26 ± 6%, p < 0.001), hemoglobin (12.8 ± 1.4 from 10.9 ± 1.0 g/dl, p < 0.001) and 6-min walked distance (274 ± 97 from 201 ± 113 m, p < 0.01) increased significantly. No significant changes were observed in the placebo arm, except for a worsening in 6-min walked distance ( p = 0.044). In conclusion, darbepoetin-α reduces circulating pro-inflammatory cytokine IL-6 and apoptotic mediator soluble Fas ligand in CHF patients with anemia, with a parallel improvement of cardiac performance and exercise capacity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
